1492 Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

1492 Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,005	Closed	-$488K	–	113
2022 Q4	$488K	Hold	12,005	–	–	0.31%	74
2022 Q3	$785K	Sell	12,005 -3	-0%	-$217	0.57%	61
2022 Q2	$730K	Buy	+12,008	New	+$706K	0.48%	71
2021 Q4	–	Sell	-9,256	Closed	-$1.04M	–	107
2021 Q3	$1.04M	Sell	9,256 -68	-0.7%	-$8.54K	0.52%	59
2021 Q2	$1.51M	Buy	9,324 +5,924	+174%	+$720K	0.77%	50
2021 Q1	$414K	Sell	3,400 -80	-2%	-$12.1K	0.24%	69
2020 Q4	$533K	Sell	3,480 -5,803	-63%	-$686K	0.31%	69
2020 Q3	$776K	Buy	9,283 +731	+9%	+$64.8K	0.58%	47
2020 Q2	$628K	Sell	8,552 -43	-0.5%	-$2.51K	0.54%	49
2020 Q1	$365K	Sell	8,595 -194	-2%	-$10K	0.44%	63
2019 Q4	$535K	Buy	+8,789	New	+$480K	0.47%	59
2019 Q1	–	Sell	-15,633	Closed	-$447K	–	86
2018 Q4	$447K	Sell	15,633 -2,132	-12%	-$74.1K	0.4%	65
2018 Q3	$788K	Buy	+17,765	New	+$930K	0.51%	63

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

1492 Capital Management's CRSP Position: Q1 2023 in Review

1492 Capital Management sold out of CRISPR Therapeutics (CRSP) in Q1 2023, closing a stake of 12,005 shares — an estimated $488K sold.

1492 Capital Management first reported a position in CRSP in Q3 2018 and held it in 13 quarters. The position peaked at $1.51M in Q2 2021. 381 funds tracked by Wall St. Rank hold CRSP as of Q1 2023.

1492 Capital Management reported no remaining CRISPR Therapeutics position as of Q1 2023 after selling out during the quarter.
1492 Capital Management sold 12,005 CRISPR Therapeutics shares in Q1 2023, an estimated $488K.
1492 Capital Management first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 13 quarters.
1492 Capital Management's CRISPR Therapeutics position peaked at $1.51M in Q2 2021.
381 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2023.

Based on 1492 Capital Management's 13F filing for Q1 2023, filed 12 May 2023.